ArticleCancer prevention research (Philadelphia, Pa.)2009
ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis.
Article in Cancer prevention research (Philadelphia, Pa.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Models of Oral Epithelial Dysplasia: A Systematic Review and Temporal Analysis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Pooled it
- Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.Journal of the National Cancer Institute · 2018Trial
- Transcriptomic atlas of premalignant oral squamous cell carcinoma in an aging mouse model reveals an enhanced immune response and dysregulation of head and neck tissue stem cells.bioRxiv : the preprint server for biology · 2026Article
- Use of 4-Nitroquinoline 1-Oxide (4NQO) in Dysplastic and Malignant Induction: In Vitro and In Vivo Studies.Biomedicines · 2025Article
- Chemopreventive Potential of Artemisinin andInternational journal of molecular sciences · 2025Article
- Histopathological characteristics of an oral epithelial dysplasia model in rats showing a negative reaction to fluorescence visualization.Scientific reports · 2025Article
- Evaluation of Therapeutic Activity of Tualang Honey on Oral Cancer: Histopathological Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- A method for scoring 4-nitroquinoline 1-oxide-induced murine esophageal squamous neoplasia.Veterinary pathology · 2023Article
- Interleukin-23 receptor defines T helper 1-like regulatory T cells in oral squamous cell carcinoma.Immunity, inflammation and disease · 2022Article
- 5-Methoxytryptophan Sensitizing Head and Neck Squamous Carcinoma Cell to Cisplatitn Through Inhibiting Signal Transducer and Activator of Transcription 3 (STAT3).Frontiers in oncology · 2022Article
- Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma.Cell reports. Medicine · 2021Article
- Article
- The Histopathology of Oral Cancer Pain in a Mouse Model and a Human Cohort.Journal of dental research · 2021Article
- The Role of Dectin-1 Signaling in Altering Tumor Immune Microenvironment in the Context of Aging.Frontiers in oncology · 2021Article
- Inhibitory Effects of Glucosylceramide on Tumorigenesis Induced by a Carcinogen in Mice.The Laryngoscope · 2020Article
- Prevention of oral carcinogenesis in rats by Dracaena cinnabari resin extracts.Clinical oral investigations · 2019Article
- Expression and oncogenic properties of membranous Notch1 in oral leukoplakia and oral squamous cell carcinoma.Oncology reports · 2018Article
- Local and systemic Curcumin C3 complex inhibits 4NQO-induced oral tumorigenesisAmerican journal of cancer research · 2018Article
- Article
- Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma.OncoTargets and therapy · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Despite numerous advances, the 5-year survival rate for head and neck squamous cell cancer (HNSCC) has remained largely unchanged. This poor outcome is due to several variables, including the development of multiple primary tumors. Therefore, it is essential to supplement early detection with preventive strategies. Using the 4-nitroquinoline 1-oxide (4-NQO) mouse model, we sought to define an appropriate dose and duration of administration that would predict the histologic timeline of HNSCC progression. Additionally, we sought to determine the timing of the onset of the angiogenic phenotype. Finally, using ABT-510 as a proof-of-principle drug, we tested the hypothesis that inhibitors of angiogenesis can slow/delay the development of HNSCC. We determined that 8 weeks of 100 microg/mL 4-NQO in the drinking water was the optimal dosage and duration to cause a sufficient incidence of hyperkeratoses, dysplasias, and HNSCC over a period of 32 weeks with minimal morbidity and mortality. Increased microvessel density and vascular endothelial growth factor expression in hyperkeratotic lesions provided evidence that the initiation of the angiogenic phenotype occurred before the development of dysplasia. Importantly, ABT-510 significantly decreased the overall incidence of HNSCC from 37.3% to 20.3% (P = 0.021) as well as the combined incidence of dysplasia and HNSCC from 82.7% to 50.6% (P < 0.001). These findings suggest that our refinement of the 4-NQO model allows for the investigation of the histologic, molecular, and biological alterations that occur during the premalignant phase of HNSCC. In addition, these data support the hypothesis that inhibitors of angiogenesis may be promising chemopreventive agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.